Stock COGT COGENT BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
7.53 USD +3.29% Intraday chart for Cogent Biosciences, Inc. +25.08% +28.06%
Feb. 27 North American Morning Briefing : Stock Futures -2- DJ
Feb. 26 Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Stock Futures -2-
DJ
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
CI
Cogent Biosciences, Inc. Announces Positive Initial Data from the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezculastinib in Patients with Advanced Systemic Metocytosis
CI
Cogent Biosciences Announces Positive Data from Part 1 of the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis
CI
Cogent Biosciences, Inc. Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
CI
Cogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Cogent Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Fed Outlook, Inflation Data Anticipated Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday
MT
Cogent Biosciences, Inc. Announces Positive Lead-In Data from Its Ongoing Phase 3 Peak Trial Evaluating the Selective KIT D816V in Patients with Gastrointestinal Stromal Tumors
CI
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Cogent Biosciences' Q4 Loss Narrows; Company Expects Cash Position to Fund Operations Into 2025
MT
Cogent Biosciences, Inc Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis
CI
Cogent Biosciences' Q3 Loss Widens
MT
Cogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Cogent Biosciences Q2 Loss Widens
MT
Cogent Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COGT Stock
  4. News Cogent Biosciences, Inc.
  5. Highlights